Producer
Recipharm
Swedish CDMO offering pMDI and DPI development and commercial manufacturing. Key inhalation CDMO with facilities in Holmes Chapel, Cheshire, UK. Offers integrated pMDI services from formulation through fill-finish at regulated facilities.
0
Inputs supplied
0
Goods downstream
1
Facilities
0
Stories
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Inhalation CDMO (pMDI, DPI, Nasal)
30%Solid Oral Dose Manufacturing
40%Sterile Manufacturing
30%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Capacity2023
Recipharm's inhalation CDMO services create a hidden concentration risk in the pharmaceutical supply chain: when a pharmaceutical company outsources its pMDI or DPI manufacturing to Recipharm, it transfers quality control responsibility and supply chain exposure to a third party. Recipharm's Holmes Chapel facility manufactures both generic and innovator brand inhalers — different products from different pharmaceutical clients manufactured in overlapping cleanroom schedules. A quality event (bacterial contamination, cross-contamination, OOS result) at a CDMO facility affects all client drug products that share manufacturing infrastructure simultaneously. During COVID-19, CDMO capacity constraints (staff restrictions, raw material shortages, priority shift to COVID drug manufacturing) cascaded to delays in non-COVID respiratory products at outsourced facilities. The CDMO model for inhalation products concentrates manufacturing risk: a quality failure at a single Cheshire CDMO plant could trigger simultaneous recalls across multiple branded and generic respiratory products from different pharmaceutical marketing companies.
Recipharm AB ↗Origin2023
Recipharm was founded in 1995 in Sweden — at the time, pharmaceutical contract manufacturing (CDMO) in Europe was a fragmented collection of small regional manufacturers. The founders saw that pharmaceutical companies were increasingly willing to outsource manufacturing to focus R&D investment on drug discovery rather than plant operations. Over 25 years, Recipharm grew through acquisitions across Sweden, France, Germany, India, and the UK into one of Europe's largest CDMOs, eventually going public on Nasdaq Stockholm (RECI-B). The Holmes Chapel, Cheshire facility — in the same northwest England pharmaceutical belt as Bespak (Norfolk) and H&T Presspart (Blackburn) — gives Recipharm inhalation CDMO capabilities adjacent to the inhaler component supply chain. Nordic Capital acquired Recipharm in 2021 (taking it private from Nasdaq Stockholm) to fund the next phase of CDMO consolidation. CDMOs like Recipharm represent the 'manufacturing-as-a-service' model applied to pharmaceutical production: drug innovators design molecules, CDMOs make them at scale.
Recipharm AB ↗